Welcome to the Board, Dipal Doshi!

A New Addition to the Azenta, Inc. Family

BURLINGTON, Mass. , Jan. 30, 2025 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) made a big announcement today at its Annual Meeting of Stockholders – the addition of Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), to its Board of Directors. Known for her expertise in the biotechnology and pharmaceutical industries, Dipal Doshi brings a wealth of knowledge and experience to the table.

Dipal Doshi is a recognized leader in the field, with a track record of success in driving innovation and growth. Her leadership at Entrada Therapeutics has been nothing short of impressive, and her appointment to the Azenta, Inc. Board of Directors signals a new chapter for the company.

With her strategic vision and proven leadership skills, Dipal Doshi is sure to make a significant impact on Azenta, Inc. and help steer the company towards continued success. We look forward to seeing what the future holds with Dipal Doshi on board!

How Does This Affect Me?

As a shareholder of Azenta, Inc., this announcement could potentially have a positive impact on your investment. With Dipal Doshi’s expertise and leadership guiding the company, there is great potential for growth and success in the future. This news is certainly something to be excited about!

How Does This Affect the World?

Dipal Doshi’s appointment to the Board of Directors at Azenta, Inc. not only signifies a new chapter for the company, but also highlights the importance of diversity and expertise in the biotechnology and pharmaceutical industries. Her leadership and vision have the potential to drive innovation and make a significant impact on the world of healthcare and beyond.

In Conclusion

We are thrilled to welcome Dipal Doshi to the Azenta, Inc. Board of Directors and look forward to the exciting opportunities and growth that lie ahead. With her leadership and expertise, the future is looking brighter than ever for Azenta, Inc. and the biotechnology industry as a whole.